Sensus Healthcare Inc (OQ:SRTS)

Business Focus: Medical Diagnostic & Testing Equipment

Apr 25, 2024 08:00 am ET
Sensus Healthcare Issues Reminder That its First Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, May 9, 2024
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on...
Apr 18, 2024 04:05 pm ET
Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May...
Mar 21, 2024 09:31 am ET
Thinking about buying stock in Healthequity, Pacira Biosciences, Interpublic Group of Companies, SIGA Technologies, or Sensus Healthcare?
NEW YORK, March 21, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HQY, PCRX, IPG, SIGA, and SRTS.
Mar 14, 2024 04:05 pm ET
Sensus Healthcare to Participate in the 36th Annual Roth Conference
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces management will participate...
Mar 13, 2024 08:00 am ET
Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the successful launch of its...
Feb 08, 2024 04:05 pm ET
Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Feb 08, 2024 08:00 am ET
Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the U.S. Patent and...
Feb 06, 2024 08:00 am ET
Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces a new multi-faceted...
Feb 01, 2024 08:00 am ET
Sensus Healthcare Announces Retirement of Director Samuel O’Rear
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O’Rear will not...
Jan 30, 2024 08:00 am ET
Sensus Healthcare to Host Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Thursday, February 8, 2024
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Jan 23, 2024 08:00 am ET
Sensus Healthcare Announces Preliminary 2023 Revenue Exceeds $23 Million
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announces preliminary...
Nov 09, 2023 04:05 pm ET
Sensus Healthcare Reports Third Quarter 2023 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Nov 02, 2023 08:00 am ET
Sensus Healthcare to Host Third Quarter 2023 Financial Results and Business Update Conference Call on Thursday, November 9, 2023
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Oct 09, 2023 08:00 am ET
Sensus Healthcare to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will...
Sep 28, 2023 08:30 am ET
Sensus Healthcare Sells Superficial Radiotherapy System to Cape Cod Hospital
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the shipment of an SRT-100+™...
Sep 26, 2023 08:00 am ET
Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces its participation in the...
Aug 08, 2023 08:30 am ET
Sensus Healthcare Announces New $3 Million Share Repurchase Program
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that its Board of Directors...
Aug 03, 2023 04:05 pm ET
Sensus Healthcare Reports Second Quarter 2023 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Jul 26, 2023 08:30 am ET
Sensus Healthcare to Host Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 3, 2023
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Jul 25, 2023 08:30 am ET
Sensus Healthcare Completes Installation of its First SRT System in Ireland
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, has installed the first SRT-100™...
Jul 06, 2023 04:05 pm ET
Sensus Healthcare Partners with MIS Healthcare to Distribute SRT Systems in the United Kingdom and Ireland
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces a partnership with MIS...
Jun 15, 2023 08:00 am ET
Sensus Healthcare to Participate in the Maxim Group Virtual Healthcare Conference Hosted by M-Vest
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces its participation in the...
May 17, 2023 08:00 am ET
Sensus Healthcare's SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients
Sensus Healthcare Inc. (Nasdaq:SRTS), the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment, is announcing that its superficial radiation therapy SRT-100 system has shown promising results...
May 03, 2023 04:05 pm ET
Sensus Healthcare Reports First Quarter 2023 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Apr 25, 2023 04:05 pm ET
Sensus Healthcare to Host First Quarter 2023 Financial Results and Business Update Conference Call on Wednesday, May 3, 2023
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Wednesday, May...
Mar 16, 2023 04:09 pm ET
Sensus Healthcare announces the Sensus Cloud™; Unveils New Features at American Academy of Dermatology (AAD) Annual Meeting in New Orleans March 17-19
Sensus Healthcare, Inc.(Nasdaq:SRTS), the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment, is proud to announce Sensus Cloud. This powerful cloud-based platform offers new innovative features...
Feb 09, 2023 04:05 pm ET
Sensus Healthcare Fourth Quarter 2022 Financial Results Include Quarterly Revenues of $13.1 Million
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions (Company or Sensus), announces...
Feb 01, 2023 04:05 pm ET
Sensus Healthcare to Host Fourth Quarter 2022 Financial Results and Business Update Conference Call on February 9, 2023
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Jan 09, 2023 08:00 am ET
Sensus Healthcare Announces Senior Management Appointments and Promotions
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, is pleased to announce the following...
Jan 05, 2023 04:05 pm ET
Sensus Healthcare Announces Preliminary Fourth Quarter 2022 Revenues
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today reports preliminary 2022 fourth...
Nov 03, 2022 04:05 pm ET
Sensus Healthcare Reports Third Quarter 2022 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Oct 27, 2022 08:00 am ET
Sensus Healthcare to Host Third Quarter 2022 Financial Results and Business Update Conference Call on November 3, 2022
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Oct 20, 2022 11:56 am ET
Sensus Healthcare Introduces Silk™ Laser Hair Removal System
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the introduction of its...
Sep 09, 2022 08:00 am ET
Sensus Healthcare to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will present...
Sep 07, 2022 08:00 am ET
Sensus Healthcare Adds Dr. Mohammad K. Khan to Medical Advisory Board
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces the addition of Mohammad K....
Aug 09, 2022 04:25 pm ET
Sensus Healthcare Launches Upgrade to its SRT-100 Vision System with New State-of-the-Art Ultrasound Capabilities
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces an upgrade to its...
Aug 04, 2022 04:05 pm ET
Sensus Healthcare Second Quarter 2022 Financial Results Feature Revenue Growth of 124%
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Jul 27, 2022 08:00 am ET
Sensus Healthcare Takes Order for 10 TransDermal Infusion Systems™ Supporting Hair Enhancement Centers Expansion Along with U.SK Under Skin’s Hair-Health Serum
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of 10 Transdermal...
Jul 26, 2022 08:00 am ET
Sensus Healthcare to Host Second Quarter 2022 Financial Results and Business Update Conference Call on August 4, 2022
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Jul 20, 2022 08:00 am ET
Colorado State University College of Veterinary Medicine and Biomedical Sciences Acquires Second SRT System from Sensus Healthcare
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces the expansion of its...
May 23, 2022 03:56 pm ET
Correction: Sensus Healthcare to Participate in the H.C. Wainwright Global Investment Conference
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will be...
May 18, 2022 04:05 pm ET
Sensus Healthcare to Participate in the H.C. Wainwright Global Investment Conference
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will be...
May 05, 2022 04:05 pm ET
Sensus Healthcare First Quarter 2022 Financial Results Feature Revenue Growth of 237%
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Apr 21, 2022 08:00 am ET
Sensus Healthcare to Host First Quarter 2022 Financial Results and Business Update Conference Call on May 5, 2022
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May...
Mar 24, 2022 08:00 am ET
Mata Mata Turtle with Squamous Cell Carcinoma Successfully Treated with Sensus Healthcare’s SRT System by Colorado State University Veterinarian
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that a mata mata turtle has...
Mar 09, 2022 04:05 pm ET
Sensus Healthcare to Present at Two Investment Conferences in March
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will be...
Mar 09, 2022 08:00 am ET
Sensus Healthcare Announces Share Repurchase Program
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that its Board of Directors...
Mar 02, 2022 08:00 am ET
Sensus Healthcare Sells its Sculptura™ Assets to Empyrean Medical Systems for $15 Million in Cash
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces it has sold its Sculptura™...
Feb 10, 2022 04:05 pm ET
Sensus Healthcare Reports Record Sales and Earnings for the 2021 Fourth Quarter
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Jan 31, 2022 04:05 pm ET
Sensus Healthcare Prepares Organization for Long-term Growth with Three Promotions
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the following promotions, all effective immediately: Vice...
Jan 26, 2022 08:30 am ET
Sensus Healthcare to Host Fourth Quarter 2021 Financial Results and Business Update Conference Call on February 10, 2022
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Jan 06, 2022 01:07 pm ET
Sensus Healthcare to Present at the H.C. Wainwright BioConnect Virtual Conference
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Joe Sardano, chairman...
Jan 05, 2022 08:00 am ET
Sensus Healthcare Expects Record 4Q 2021 Sales and Continued Growth in 1Q 2022; Profiles New Product at the 2022 Winter Clinical Dermatology Conference
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it expects record sales...
Dec 01, 2021 08:30 am ET
Sensus Healthcare Signs Exclusive U.S. Distribution Agreement with Mattioli Eng. Italia for its TransDermal Infusion System
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the signing of an exclusive...
Nov 04, 2021 04:02 pm ET
Sensus Healthcare Reports Third Quarter 2021 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Oct 20, 2021 08:30 am ET
Sensus Healthcare to Host Third Quarter 2021 Financial Results and Business Update Conference Call on November 4, 2021
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Oct 15, 2021 08:30 am ET
Sensus Healthcare to Participate in Fireside Chat Hosted by Maxim Group and M-Vest
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Joseph Sardano,...
Oct 12, 2021 08:30 am ET
Chinese Health Authority Renews License for Sensus Healthcare’s SRT-100™ for Five More Years
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the Chinese Health...
Oct 07, 2021 08:30 am ET
Sensus Healthcare Announces Presentations, Demonstrations and Exhibit Booth at the 2021 Fall Clinical Conference in Las Vegas
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the company will be...
Sep 08, 2021 09:00 am ET
Sensus Healthcare to Participate at H.C. Wainwright 23rd Annual Global Investment Conference
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced that Joe Sardano, chairman...
Aug 05, 2021 04:05 pm ET
Sensus Healthcare Reports Second Quarter 2021 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Jul 29, 2021 08:00 am ET
Sensus Healthcare to Host Second Quarter 2021 Financial Results and Business Update Conference Call on August 5, 2021
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Jul 22, 2021 08:00 am ET
Sensus Healthcare Announces Participation in A.G.P.’s Virtual MedTech Summer Conference on July 29, 2021
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced that management will...
May 06, 2021 04:05 pm ET
Sensus Healthcare Reports First Quarter 2021 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Apr 29, 2021 04:00 pm ET
Sensus Healthcare to Host First Quarter 2021 Financial Results and Business Update Conference Call on May 6, 2021
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May...
Mar 16, 2021 08:00 am ET
Colorado State University, Flint Animal Cancer Center Applies Sensus Healthcare’s SRT Non-Surgical Treatment to Animal Care
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced today that the first canine...
Mar 08, 2021 04:15 pm ET
Sensus Healthcare to Participate in Three Investment Conferences During the Month of March
Sensus Healthcare, Inc. (NASDAQ: SRTS), a  medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced that Joe Sardano,...
Feb 25, 2021 04:05 pm ET
Sensus Healthcare Reports Fourth Quarter and Full Year 2020 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Feb 23, 2021 08:00 am ET
Sensus Healthcare Granted U.S. Patent for Three-Dimensional Beam Forming X-Ray Source
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced that the U.S. Patent...
Feb 18, 2021 08:00 am ET
Sensus Healthcare to Host Fourth Quarter 2020 Financial Results and Business Update Conference Call on February 25, 2021
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Jan 06, 2021 09:32 am ET
Holy Name Medical Center in Teaneck, New Jersey Acquires Sensus Healthcare’s Low-dose Radiation Therapy System to Treat Pneumonia in COVID-19 Patients
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced Holy Name Medical...
Dec 15, 2020 08:00 am ET
Sensus Healthcare Engages Ekpac Healthcare Ltd. as New Exclusive Distributor in China for SRT-100™ Systems
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it has entered into a...
Dec 08, 2020 08:00 am ET
Sensus Healthcare Announces CMS Sets Rates Higher for SRT Reimbursement
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the Centers for...
Dec 01, 2020 08:00 am ET
Sensus Healthcare Announces Study Showing Single Low Dose of Superficial Radiation Therapy Prevents Keloid Recurrence Following Surgical Excision
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the publication of a...
Nov 05, 2020 04:02 pm ET
Sensus Healthcare Reports Third Quarter 2020 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Nov 05, 2020 08:00 am ET
Sensus Healthcare Appoints Megan Cornish to its Board of Directors
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the appointment of Megan...
Oct 29, 2020 11:18 am ET
Sensus Healthcare to Host Third Quarter 2020 Financial Results and Business Update Conference Call on November 5, 2020
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Oct 22, 2020 08:00 am ET
Sensus Healthcare Announces Publication of Study Showing Use of Superficial Radiation Therapy Post-Keloidectomy Prevents Keloid Recurrence
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the publication of a...
Aug 06, 2020 04:02 pm ET
Sensus Healthcare Reports Second Quarter 2020 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Aug 05, 2020 08:30 am ET
American Society of Radiologic Technologists Approves Sensus Healthcare’s SRT Systems for Continuing Education Units
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, and the leading provider of superficial radiotherapy (SRT), reports...
Aug 04, 2020 08:30 am ET
Sensus Healthcare Acquires Two Mobile Aesthetic Laser Companies in Florida
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the acquisition of two...
Jul 30, 2020 08:30 am ET
Sensus Healthcare to Host Second Quarter 2020 Financial Results and Business Update Conference Call on August 6, 2020
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Jul 28, 2020 08:30 am ET
Sensus Healthcare Names Hoi-Bun “Benson” Suen Vice President of International Sales, Ships SRT-100™ to China
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the appointment of Hoi-Bun...
Jul 14, 2020 08:00 am ET
Evidence-Based Guidelines Issued by ASTRO Support Sensus Healthcare’s SRT Technology as the First-Line Alternative to Surgery for Treating Non-Melanoma Skin Cancer
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, and the leading provider of superficial radiotherapy (SRT), reports...
Jul 13, 2020 04:02 pm ET
Sensus Healthcare to Present at COVID-19 Webinar Hosted by Maxim Group on July 16th
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, Sensus’ chief executive officer has...
Jun 30, 2020 08:30 am ET
Sensus Healthcare’s CEO to Participate in Dermatology Practice Panel Discussion as Part of the Fall Clinical Virtual Grand Rounds Weekly Series
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that Joe Sardano, the company’s chief executive officer, will...
Jun 24, 2020 08:30 am ET
Sensus Healthcare Announces CME Presentation by Dr. Jeffrey S. Fromowitz Today at the Fall Clinical Virtual Grand Rounds Series
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that Jeffrey S. Fromowitz, M.D. will discuss the use of...
Jun 03, 2020 08:30 am ET
Sensus Healthcare and David Goldberg, M.D., J.D. to Host a Virtual Program on Dermatology Medical and Legal Issues in the Era of COVID-19
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that it will host a program titled “Medical-Legal Issues in...
May 07, 2020 04:02 pm ET
Sensus Healthcare Reports First Quarter 2020 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Apr 30, 2020 08:00 am ET
Sensus Healthcare to Host First Quarter 2020 Financial Results and Business Update Conference Call on May 7, 2020
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May...
Mar 03, 2020 08:30 am ET
Sensus Healthcare Announces Publication of Research on Long-term Efficacy and Safety of Superficial Radiation Therapy in Journal of Drugs in Dermatology
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced that results from a...
Feb 13, 2020 04:02 pm ET
Sensus Healthcare Reports Fourth Quarter and Full Year 2019 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Feb 06, 2020 08:30 am ET
Sensus Healthcare to Host Fourth Quarter 2019 Financial Results and Business Update Conference Call on February 13, 2020
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Jan 22, 2020 08:30 am ET
Sensus Healthcare Announces Sculptura™ Shipment to California-based Medical Center Third Sculptura system sold worldwide
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, is pleased to announce it has shipped...
Jan 06, 2020 04:05 pm ET
Sensus Healthcare Announces Management Promotions
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces management promotions to...
Nov 21, 2019 08:30 am ET
Sensus Healthcare to Present at the Piper Jaffray 31st Annual Healthcare Conference
Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced today that Joe Sardano, CEO...
Nov 06, 2019 04:02 pm ET
Sensus Healthcare Reports Third Quarter 2019 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the...
Nov 01, 2019 09:57 am ET
Sensus Healthcare to Host Third Quarter 2019 Financial Results and Business Update Conference Call on November 6, 2019
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Wednesday,...
Aug 08, 2019 04:05 pm ET
Sensus Healthcare Reports Second Quarter 2019 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions, announces financial results for...
Jul 30, 2019 02:57 pm ET
Sensus Healthcare to Host Second Quarter 2019 Financial Results and Business Update Conference Call on August 8, 2019
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday,...
Jun 10, 2019 11:00 am ET
Sensus Healthcare to Present at the Raymond James Inaugural Life Sciences and MedTech Conference
Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, CEO of the Company, will present a...
May 15, 2019 08:30 am ET
Sensus Healthcare to Present at the 20th Annual B. Riley FBR Investor Conference
BOCA RATON, Fla., May 15, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, CEO of the Company, will present a corporate overview at the 20th Annual B. Riley FBR Investor Conference on Thursday, May 23 at 11:00 a.m. Pacific time. The conference will be held May 22-23., 2019 at the Beverly Hilton Hotel in Beverly Hills, Calif.
May 09, 2019 04:02 pm ET
Sensus Healthcare Reports First Quarter 2019 Financial Results
BOCA RATON, Fla., May 9, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces financial results for the three months ended March 31, 2019.
May 08, 2019 08:30 am ET
Sensus Healthcare Awarded Brachytherapy Products Agreement with Premier
BOCA RATON, Fla., May 8, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in novel radiation oncology technologies and solutions, has been awarded a group purchasing agreement for Brachytherapy Products with Premier. Effective August 1, 2019, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Sensus' SRT-100™ Superficial Radiation Therapy systems.
Apr 25, 2019 04:00 pm ET
Sensus Healthcare to Host First Quarter 2019 Financial Results and Business Update Conference Call on May 9, 2019
BOCA RATON, Fla., April 25, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 9, 2019 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter ended March 31, 2019. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Apr 24, 2019 08:30 am ET
Sensus Healthcare Signs R&D Agreement to Collaborate with Perelman School of Medicine at the University of Pennsylvania on World's First Sculptura™ Intraoperative Radiation Therapy System
BOCA RATON, Fla., April 24, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in novel radiation oncology technologies and solutions, today announced that the Company has signed a research and development agreement with the Perelman School of Medicine at the University of Pennsylvania to collaborate with the radiation oncology department on clinical research and development for Sensus' Sculptura™ robotic intraoperative radiation therapy (IORT) system.
Apr 23, 2019 08:30 am ET
Five-Year Retrospective Study Shows 98.9 Percent Cure Rate for Non-Melanoma Skin Cancer Patients Treated with Sensus Healthcare's Superficial Radiation Therapy
BOCA RATON, Fla., April 23, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in non-invasive treatments for both oncological and non-oncological conditions, announced today topline results from a five-year retrospective study of non-melanoma skin cancer (NMSC) patients treated with Superficial Radiation Therapy (SRT) (ClinicalTrials.gov Identifier: NCT03693937). The study, which was conducted across four U.S. sites, showed a 98.9 percent cure rate among 516 male and female patients. These patients had a collective total of 776 NMSC lesions tr
Apr 11, 2019 08:40 am ET
Consolidated Research: 2019 Summary Expectations for ZIOPHARM Oncology, Airgain, Liquidity Services, Kindred Biosciences, Landmark Infrastructure Partners LP, and Sensus Healthcare — Fundamental Analy
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Airgain, Inc. (NASDAQ:AIRG), Liquidity...
Mar 13, 2019 08:00 am ET
Sensus Healthcare to Present at the 31st Annual ROTH Conference
BOCA RATON, Fla., March 13, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, CEO of the Company, will present a corporate overview at the 31st Annual ROTH Conference on Tuesday, March 19 at 3:30 p.m. Pacific time. The conference will be held March 17-19, 2019 at The Ritz Carlton, Laguna Niguel in Orange County, Calif. 
Mar 12, 2019 08:30 am ET
Sensus Healthcare Launches SRT University, an Online Portal to Support Physicians
BOCA RATON, Fla., March 12, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today the launch of SRT University, an online portal to support physicians using Sensus devices and technology. The new online portal provides physicians and their staff access to Sensus' depository of information related to superficial radiation therapy (SRT) and intraoperative radiotherapy (IORT).
Feb 28, 2019 07:00 am ET
Sensus Healthcare Appoints Dr. Ziv Karni as Chief Scientific Officer
BOCA RATON, Fla., Feb. 28, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that the Company has appointed Dr. Ziv Karni to the role of Chief Scientific Officer, effective immediately. Dr. Karni, a pioneer in medical technology research and development, has more than 30 years of experience in the development and sales of medical and aesthetic technologies. He will report to Joe Sardano, Sensus Healthcare CEO.
Feb 26, 2019 07:00 am ET
U.S. FDA Grants Market Clearance to Sensus Healthcare's New Sculptura™ Radiation Oncology System
BOCA RATON, Fla., Feb. 26, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted market clearance for the Company's groundbreaking Sculptura™ radiation oncology system. A single treatment during surgery, Sculptura™ can provide cancer patients and physicians a single radiation treatment at the point of surgery.
Feb 14, 2019 03:02 pm ET
Sensus Healthcare Fourth Quarter Financial Results Feature Record Revenue and Continued Double-digit Growth
BOCA RATON, Fla., Feb. 14, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three and 12 months ended December 31, 2018.
Feb 14, 2019 07:30 am ET
Leading Dermatologists Develop Consensus Guidelines for the Use of Superficial Radiation Therapy to Treat Non-Melanoma Skin Cancers and Keloids
BOCA RATON, Fla., Feb. 14, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloid scars with Image-Guided Superficial Radiation Therapy (IGSRT), announced today the publication of consensus guidelines on the use of Superficial Radiation Therapy (SRT) for treating both NMSC and recurrent keloid scars in February 2019 issue of The Journal of Clinical and Aesthetic Dermatology. 
Feb 12, 2019 07:45 am ET
Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare's SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities
BOCA RATON, Fla., Feb. 12, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), announces the publication of a new retrospective study that showed a high cure rate exceeding 97 percent among older patients (mean age: 82.5 years) being treated for basal and squamous cell carcinomas on their lower extremities with Sensus' SRT-100TM Superficial Radiation Therapy.
Jan 30, 2019 08:00 am ET
Sensus Healthcare to Host Fourth Quarter and Full Year 2018 Financial Results and Business Update Conference Call on February 14, 2019
BOCA RATON, Fla., Jan. 30, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management will hold a conference call on Thursday, February 14, 2019  at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year ended December 31, 2018. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Dec 06, 2018 07:45 am ET
Sensus Healthcare Announces Low 3% Keloid Recurrence in Multicenter Case Series of 297 Patients Treated with Superficial Radiation Therapy
BOCA RATON, Fla., Dec. 6, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), announced today positive results of a multicenter case series of patients treated with the SRT-100™ following complete surgical keloidectomy. Of the 297 keloidectomy patients treated post-operatively with superficial radiation, there were only nine cases of observed clinical keloid recurrences, or a recurrence rate of 3%. The results of
Nov 29, 2018 07:45 am ET
Sensus Healthcare Installs First Groundbreaking SRT-100+ Superficial Radiation Therapy System for Treating Keloid Scars
BOCA RATON, Fla., Nov. 29, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), has installed its first SRT-100+ system at Hillcrest Plastic Surgery in Orlando, Fla., specifically for the treatment of keloid scars. Earlier this year, Sensus received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its new SRT-100+, which adds several innovative features to Sensus' existing SRT-100 pr
Nov 15, 2018 08:10 am ET
Report: Exploring Fundamental Drivers Behind Affimed N.V, Sensus Healthcare, Lifetime Brands, SigmaTron International, Salem Media Group, and Origin Agritech — New Horizons, Emerging Trends, and Upcom
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Affimed N.V. (NASDAQ:AFMD), Sensus Healthcare, Inc. (NASDAQ:SRTS),...
Nov 01, 2018 04:02 pm ET
Sensus Healthcare Third Quarter Financial Results Feature Revenue Growth of 32%
BOCA RATON, Fla., Nov. 1, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three and nine months ended September 30, 2018.
Oct 22, 2018 08:30 am ET
Sensus Healthcare to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 1, 2018
BOCA RATON, Fla., Oct. 22, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management will hold a conference call on Thursday, November 1, 2018 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter ended September 30, 2018. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Oct 17, 2018 08:30 am ET
Sensus Healthcare Brings Groundbreaking SRT-100 Vision System to Israel's Largest Hospital for Skin Cancer and Keloid Treatment
BOCA RATON, Fla., Oct. 17, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced that the Company has shipped  its third SRT-100 Vision™ system to Israel, with the newest unit located at the Sheba Medical Center in Tel HaShomer, near Tel Aviv. The other two previously installed units reside at the Ichilov Hospital in Tel Aviv and Beilinson Hospital / Rabin Medical Center in Petah Tikva.
Oct 16, 2018 08:30 am ET
South Florida Business Journal Recognizes Sensus Healthcare's Chief Technology Officer at 2018 Technology Awards
BOCA RATON, Fla., Oct. 16, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced that the South Florida Business Journal has recognized the Company's Chief Technology Officer, Kal Fishman, as a finalist at this year's Technology Awards. The ceremony was held on Thursday, Oct. 11, 2018, at the Signature Grand in Davie, Fla.
Sep 21, 2018 11:06 am ET
Sensus Healthcare, Inc. Announces Underwriters' Exercise of Option
BOCA RATON, Fla., Sept. 21, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it has issued an additional 330,882 shares of its common stock pursuant to the exercise in full of the underwriters' option received in connection with Sensus' recently completed public offering of its common stock.
Sep 17, 2018 12:29 pm ET
Sensus Healthcare, Inc. Announces Closing of Public Offering of Common Stock
BOCA RATON, Fla., Sept. 17, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it completed a public offering of 2,205,882 shares of its common stock, par value $0.01 per share, at a public offering price of $6.80 per share. All of the shares were offered by Sensus. The shares are listed on The Nasdaq Capital Market under the ticker symbol "SRTS."  Total proceeds to Sensus from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $15 million. Sensus has granted the underwriters a 30-day o
Sep 13, 2018 09:28 am ET
Sensus Healthcare, Inc. Announces Pricing of Public Offering of Common Stock
BOCA RATON, Fla., Sept. 13, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it has priced an underwritten public offering of 2,205,882 shares of its common stock, par value $0.01 per share, at a public offering price of $6.80 per share. Sensus has granted a 30-day option to purchase up to an additional 330,882 shares pursuant to the underwriting agreement.
Sep 12, 2018 04:19 pm ET
Sensus Healthcare, Inc. Announces Commencement of Public Offering of Common Stock
BOCA RATON, Fla., Sept. 12, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it commenced a public offering of its common stock, par value $0.01 per share.
Sep 07, 2018 08:04 am ET
Sensus Healthcare Presents at National Cancer Care Alliance Leadership Board and Practice Quarterly Meeting
BOCA RATON, Fla., Sept. 7, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, President and Chief Executive Officer, participated at the National Cancer Care Alliance (NCCA) Leadership Board and Practice Quarterly Meeting, which took place Thursday, August 30 through Friday, August 31, 2018, in Chicago.
Aug 27, 2018 08:00 am ET
Sensus Healthcare to Participate in Two Upcoming Investor Conferences
BOCA RATON, Fla., Aug. 27, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, President and Chief Executive Officer, will participate at two investor conferences in September 2018, as follows:
Aug 02, 2018 04:01 pm ET
Sensus Healthcare Second Quarter Financial Results Feature Continued Strong Revenue Growth
BOCA RATON, Fla., Aug. 2, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three and six months ended June 30, 2018.
Aug 02, 2018 08:05 am ET
Sensus Healthcare Receives FDA 501(k) Clearance to Market Next-Generation SRT-100+ Superficial Radiation Therapy for Treating Non-Melanoma Skin Cancer and Keloids
BOCA RATON, Fla., Aug. 2, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced that the Company has received 501(k) clearance from the U.S. Food and Drug Administration (FDA) to market its new SRT-100+, the next-generation Superficial Radiation Therapy solution that adds several innovative features to Sensus' existing SRT-100 product.
Jul 31, 2018 08:00 am ET
Sensus Healthcare CEO Receives "Innovator of the Year" Award at The Aesthetic Show 2018
BOCA RATON, Fla., July 31, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced that the Company's CEO, Joe Sardano, has been named non-physician, nonsurgical "Innovator of the Year" at the 2018 Aesthetic Awards, hosted by The Aesthetic Channel, a media resource for cosmetic doctors. Sensus Healthcare was also named a runner-up for "Company Nonsurgical Innovator of the Year."
Jul 24, 2018 08:30 am ET
Sensus Healthcare to Host Second Quarter 2018 Financial Results and Business Update Conference Call on August 2, 2018
BOCA RATON, Fla., July 24, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management will hold a conference call on Thursday, August 2, 2018 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter ended June 30, 2018. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Jul 12, 2018 08:00 am ET
Sensus Healthcare Announces Strategic Agreement with SkinCure Oncology
BOCA RATON, Fla., July 12, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced a strategic agreement focused on marketing the SRT-100 Vision™ with SkinCure Oncology, a leading turnkey provider of IGSRT solutions in the dermatology industry. SkinCure uses the same quality and safety features of leading cancer center models for the delivery of Sensus' most technically advanced and innovative device
Jul 10, 2018 08:00 am ET
Sensus Healthcare and CellMark Medical Partner to Accelerate International Expansion and Growth for Innovative Oncology and Aesthetic Solutions
BOCA RATON, Fla., July 10, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), and CellMark Medical, a global supply chain service company, today announced a new partnership to support and accelerate international growth and encourage worldwide adoption of Sensus' groundbreaking technologies for oncological and aesthetic indications.  
Jun 25, 2018 08:00 am ET
Sensus Healthcare to Join Russell Microcap® Index
BOCA RATON, Fla., June 25, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that it is set to join the Russell Microcap® Index at the conclusion of the Russell U.S. Indexes annual reconstitution, effective before the U.S. market opens on June 25th.
Jun 12, 2018 07:30 am ET
Sensus Healthcare to Participate in Panel Discussion at the Cantor Fitzgerald Dermatology & Aesthetics Summit
BOCA RATON, Fla., June 12, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare, will participate in a panel discussion, titled "New Treatments for Rare/Orphan Diseases and Oncologic Conditions," at the Cantor Fitzgerald Dermatology & Aesthetics Summit on Tuesday, June 19 at 2:00pm ET in New York.  The Summit is being held at the Westin Grand Cent
May 08, 2018 08:30 am ET
Sensus Healthcare Appoints Dr. Isabelle Raymond as Vice President, Clinical Development
BOCA RATON, Fla., May 8, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced the appointment of Dr. Isabelle Raymond, PhD, as Vice President, Clinical Development. Dr. Raymond, who will report to Joe Sardano, Sensus CEO, brings 14 years of medical device and pharmaceutical industry experience to the Company.
May 03, 2018 04:00 pm ET
Sensus Healthcare Reports First Quarter Financial Results Featuring 37% Revenue Growth
BOCA RATON, Fla., May 3, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three months ended March 31, 2018.
May 01, 2018 08:30 am ET
Sensus Healthcare Appoints Rita Gable as Vice President of Sales - Oncology
BOCA RATON, Fla., May 1, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced today the appointment of Rita Gable as its Vice President of Sales – Oncology, effective immediately. Ms. Gable, who will report to Joe Sardano, Sensus CEO, has 15 years of sales experience, specializing in the oncology market. 
Apr 26, 2018 08:00 am ET
Sensus Healthcare to Host First Quarter 2018 Financial Results and Business Update Conference Call on May 3, 2018
BOCA RATON, Fla., April 26, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management will hold a conference call on Thursday, May 3, 2018 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter ended March 31, 2018. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Apr 19, 2018 08:30 am ET
Sensus Healthcare Expands International Business to Meet Rising Patient Demand for Non-Invasive Skin Cancer and Keloid Treatments
BOCA RATON, Fla., April 19, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced today that the Company is significantly expanding its global business with SRT to meet growing consumer demand for non-invasive, highly effective skin cancer and keloid treatments. Rick Golin, Executive Vice President of Oncology and International Sales, will spearhead this expansion, overseeing all international distributors. As part of this, he
Mar 08, 2018 07:30 am ET
Sensus Healthcare to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
BOCA RATON, Fla., March 8, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), and multi-platform state of the art aesthetic lasers, today announced the Company will present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) on Saturday, March 17, 2018. The conference will be held March 15-17, 2018 at the Intercontinental Hotel in Hangzhou, China.
Mar 05, 2018 07:30 am ET
Sensus Healthcare Launches New Line of Laser Systems to Provide Patients with Full Spectrum of Clinical and Aesthetic Dermatological Solutions
BOCA RATON, Fla., March 5, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced today that the Company has launched Sensus Laser Systems, a unique multi-platform line of high-quality, cost-effective dermatological lasers to compliment Sensus' existing SRT system. Sensus Laser Systems includes applications for hair and tattoo removal, acne lesion correction, skin rejuvenation and pigmentation / large pore treatment.
Feb 07, 2018 07:30 am ET
Sensus Healthcare Opens Tel Aviv Office to Expand Footprint in Israel, the Middle East & Europe
BOCA RATON, Fla., Feb. 7, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced today that the Company is opening a new office in Tel Aviv to deepen its presence in Israel, the Middle East and Europe—while continuing to bring Sensus' innovative SRT treatment to patients all over the world who are afflicted with both non-melanoma skin cancers and keloids.
Feb 05, 2018 07:30 am ET
Sensus Healthcare Launches Collaboration with BirchBioMed to Treat and Prevent Scarring for Keloids Patients Around the World
BOCA RATON, Fla., Feb. 5, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced today Sensus' collaboration with BirchBioMed Inc., a biomedical company focused on anti-scarring drugs, to treat and prevent scarring more effectively for patients who are afflicted with keloids.
Feb 01, 2018 03:01 pm ET
Sensus Healthcare Reports Record Revenue for 2017 Fourth Quarter and Full Year
BOCA RATON, Fla., Feb. 1, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three and 12 months ended December 31, 2017.
Feb 01, 2018 12:45 pm ET
Sensus Healthcare, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 1, 2018 / Sensus Healthcare, Inc. (NASDAQ: SRTS) will be discussing their earnings results in their Q4 Earnings Call to be held on February 1, 2018 at 4:30 PM Eastern Time.
Jan 25, 2018 07:30 am ET
Sensus Healthcare to Host Fourth Quarter and Fiscal Year 2017 Financial Results and Business Update Conference Call on February 1, 2018
BOCA RATON, Fla., Jan. 25, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management will hold a conference call on Thursday, February 1, 2018 at 4:30 p.m. ET to discuss the financial results for the fourth quarter and year ended December 31, 2017. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Nov 02, 2017 05:01 pm ET
Sensus Healthcare Reports Third Quarter Financial Results Featuring Revenue up 44%
BOCA RATON, Fla., Nov. 2, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three and nine months ended September 30, 2017.
Nov 01, 2017 08:30 am ET
Sensus Healthcare Launches SRT-100 in China for Keloid Prevention and Treatment at Major Dermatology Conference, Extends Distribution Agreement with Chindex Medical
BOCA RATON, Fla., Nov. 1, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces it has launched the SRT-100™ in China for the treatment and prevention of keloids with Chindex Medical Limited. Sensus also announces the extension of its exclusive distribution agreement with Chindex Medical, a joint venture between Fosun Pharma and Chindex International, Inc., through 2020.
Oct 31, 2017 08:30 am ET
Sensus Healthcare Announces Clearance to Market the SRT-100™ in Mexico
BOCA RATON, Fla., Oct. 31, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that the SRT-100™ is now cleared for sale in Mexico.  The system is approved for the treatment of non-melanoma skin cancer and keloids and will be placed on the National Registry upon its next publication by February 2018.  Sensus has engaged Cyber Robotics of Mexico City as its distribution partner.
Oct 25, 2017 10:00 am ET
Sensus Healthcare to Host Third Quarter 2017 Financial Results and Business Update Conference Call on November 2, 2017
BOCA RATON, Fla., Oct. 25, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radiation Therapy (SRT), announces that management will hold a conference call on Thursday, November 2, 2017 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2017. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Oct 23, 2017 09:30 am ET
Stratpharma AG & Sensus Healthcare Announce Strategic Collaboration for Transformative Superficial Radiation Therapy & Post-Treatment Care
SAN DIEGO, Oct. 23, 2017 /PRNewswire/ -- Stratpharma Inc. USA, a U.S. subsidiary of Stratpharma AG, the Swiss company that specializes in innovative film-forming full-contact topical medical products to improve medical and aesthetic outcomes in post-procedure care in aesthetic dermatology, plastic surgery and radiation oncology, and Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radiation Therapy (SRT), announced today a new collaboration that's focused on advancing the treatment and hea
Oct 11, 2017 08:30 am ET
Sensus Healthcare to Present at Dawson James Securities 3rd Annual Small Cap Growth Conference
BOCA RATON, Fla., Oct. 11, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radiation Therapy (SRT), today announced that management will present at the Dawson James Securities 3rd Annual Small Cap Growth Conference on Thursday, October 19, 2017 at 12:00 p.m. Eastern time. The conference will be held at the Wyndham Grand Hotel in Jupiter, Florida on October 18-19, 2017.
Oct 09, 2017 09:30 am ET
Sensus Healthcare Details Abstract on Keloid Treatment with SRT at the 2017 American Society for Dermatologic Surgery Annual Meeting
BOCA RATON, Fla., Oct. 9, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radiation Therapy (SRT), announced today that an abstract was presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting, which took place on Oct. 5-8 in Chicago, illustrating the low recurrence rate of keloids post-keloidectomy with a biological effective dose 30 (BED 30) of SRT.
Oct 09, 2017 08:30 am ET
Sensus Healthcare Announces Abstract on Treatment of Keloids with SRT at the 2017 American Society for Dermatologic Surgery Annual Meeting
BOCA RATON, Fla., Oct. 9, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radiation Therapy (SRT), announces that at the American Society for Dermatologic Surgery (ASDS) annual meeting, which took place October 5th-8th in Chicago, an abstract was presented illustrating the low recurrence rate of keloids post keloidectomy with a biological effective dose 30 (BED 30) of SRT. Recurrences of keloids at sites of previously excised keloids are notorious in that approximatel
Sep 20, 2017 08:30 am ET
Sensus Healthcare to Present at the Ladenburg Thalmann 2017 Healthcare Conference
BOCA RATON, Fla., Sept. 20, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that management will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 26, 2017 at 4:00 p.m. Eastern time. The conference is being held that day at the Sofitel Hotel in New York City.
Sep 11, 2017 08:30 am ET
Sensus Healthcare Cancels Presentation to Rodman & Renshaw Global Investment Conference due to Hurricane Irma
BOCA RATON, Fla., Sept. 11, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that management will not be able to present at the Rodman & Renshaw Global Investment Conference due to the impact of Hurricane Irma. The presentation was to have been made at 4:15 p.m. Eastern time today.
Aug 23, 2017 04:01 pm ET
Sensus Healthcare to Present at the 6th Annual Liolios Gateway Conference on September 6, 2017
BOCA RATON, Fla., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq:SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), has been invited to present at the 2017 Gateway Conference, which is being held on September 6-7, 2017 at the Four Seasons Hotel San Francisco....
Aug 03, 2017 05:01 pm ET
Sensus Healthcare Reports Record Second Quarter Financial Results
BOCA RATON, Fla., Aug. 3, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three and six months ended June 30, 2017.
Jul 26, 2017 08:30 am ET
Sensus Healthcare Receives Regulatory Approval to Sell the SRT-100™ in China for the Treatment and Prevention of Keloids
BOCA RATON, Fla., July 26, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that the SRT-100™ has been cleared by the China Food and Drug Administration (CFDA) to treat and prevent keloids. China accounts for more than 20% of the world's patient population.
Jul 25, 2017 09:30 am ET
Sensus Healthcare to Host Second Quarter 2017 Financial Results and Business Update Conference Call on August 3, 2017
BOCA RATON, Fla., July 25, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), announces that management will hold a conference call beginning at 4:30 p.m. Eastern Time on Thursday, August 3, 2017 to discuss the financial results for the second quarter of 2017. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
May 24, 2017 09:30 am ET
Sensus Healthcare Awarded 2017 Technology Leader of the Year for Disruptive Technology from Greater Miami Chamber of Commerce
BOCA RATON, Fla., May 24, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions, such as keloids with Superficial Radiotherapy (SRT), has been awarded the 2017 Technology Leader of the Year for the Disruptive Technology category by The Greater Miami Chamber of Commerce. Sensus provides a non-invasive, cost-effective treatment for NMSC and keloids using the Company's proprietary, FDA-cleared, low-energy X-ray radiation technology known as SRT, which has effectively an
May 04, 2017 05:01 pm ET
Sensus Healthcare First Quarter Financial Results Feature Revenues up 43%
BOCA RATON, Fla., May 4, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three months ended March 31, 2017.
Apr 27, 2017 09:30 am ET
Sensus Healthcare to Host First Quarter 2017 Financial Results and Business Update Conference Call on May 4, 2017
BOCA RATON, Fla., April 27, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), announced today that management will hold a conference call beginning at 4:30 p.m. Eastern Time on Thursday, May 4, 2017 to discuss the financial results for the first quarter of 2017. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Apr 24, 2017 05:34 pm ET
Sensus Healthcare issues letter to stockholders
BOCA RATON, Fla., April 24, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), announces that Joe Sardano, chairman and chief executive officer issued today the following letter to stockholders:
Mar 07, 2017 10:30 am ET
Sensus Healthcare to Present at the 29th Annual ROTH Conference
BOCA RATON, Fla., March 7, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), today announced that Joe Sardano, the Company's chief executive officer, will present a corporate overview at the 29th Annual ROTH Conference on Wednesday, March 15th  at 8:30 a.m. Pacific time.  The conference will be held at the Ritz-Carlton, Laguna Niguel in Dana Point, Calif. from March 13th  through 15th.
Feb 07, 2017 08:30 am ET
Sensus Healthcare to Participate in 2017 South Beach Symposium on February 9 - 12 in Miami
BOCA RATON, Fla., Feb. 7, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that the company will participate in the 2017 South Beach Symposium (SBS) at the Loews Miami Beach Hotel in Miami Beach, Fla., on February 9–12.
Feb 02, 2017 04:05 pm ET
Sensus Healthcare Reports Fourth Quarter and Full Year 2016 Results
BOCA RATON, Fla., Feb. 2, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today reported its financial results for the three-month period and full year ended December 31, 2016.
Jan 19, 2017 08:30 am ET
Sensus Healthcare to Announce Fourth Quarter and Full Year 2016 Results on February 2, 2017
BOCA RATON, Fla., Jan. 19, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced that it will report its fourth quarter and full year 2016 financial results on Thursday, February 2, 2017 after the market close.
Jan 03, 2017 08:30 am ET
Sensus Healthcare to Participate in Annual JP Morgan Healthcare Conference Week on January 9th - 11th in San Francisco
BOCA RATON, Fla., Jan. 3, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions such as keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, CEO and Arthur Levine, CFO will participate in the Annual JP Morgan Healthcare Conference Week to be held in San Francisco on Monday, January 9th through Wednesday, January 11th.
Dec 13, 2016 04:05 pm ET
Sensus Healthcare Receives the BioFlorida Company of the Year Award
BOCA RATON, Fla., Dec. 13, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions such as keloids with superficial radiation therapy (SRT), announced today that it has been named the winner of the BioFlorida Company of the Year Award at the 2016 BioFlorida Annual Conference in Jacksonville, Florida.  
Nov 16, 2016 08:30 am ET
Sensus Healthcare to Participate in Two Upcoming Investor Conferences on November 30th and December 1st
BOCA RATON, Fla., Nov. 16, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that Joe Sardano, CEO and Arthur Levine, CFO will participate in two upcoming investor conferences:
Nov 03, 2016 05:05 pm ET
Sensus Healthcare Reports Third Quarter 2016 Results
BOCA RATON, Fla., Nov. 3, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today reported its financial results for the three and nine month periods ended September 30, 2016.
Oct 20, 2016 09:30 am ET
Sensus Healthcare to Announce Third Quarter 2016 Results on November 3, 2016
BOCA RATON, Fla., Oct. 20, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced that it will report its third quarter 2016 financial results on Thursday, November 3, 2016 after the market close.
Oct 06, 2016 09:30 am ET
Sensus Healthcare to Participate in Important Dermatological and Institutional Investor Conferences from October 20th to October 23rd
BOCA RATON, Fla., Oct. 6, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that management will participate in two upcoming conferences:
Sep 07, 2016 09:30 am ET
Sensus Healthcare, Inc. Receives the Frost & Sullivan 2016 Global Non-melanoma Skin Cancer Therapy Technology Leadership Award
BOCA RATON, Fla., Sept. 7, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions such as keloids with superficial radiation therapy (SRT), announced today it has been named the winner of the Frost & Sullivan 2016 Global Non-melanoma Skin Cancer Therapy Technology Leadership Award for its innovative therapy treatment technology. Sensus Healthcare scored an average 9.5 out of 10 possible points on the Frost & Sullivan Technology Leadership Scorecard across 10 diff
Aug 31, 2016 09:30 am ET
Sensus Healthcare to Sponsor First International Keloid Symposium on September 8 and 9 in New York
BOCA RATON, Fla., Aug. 31, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that the Company will sponsor the First International Keloid Symposium to be held at The Rockefeller University in New York on Thursday, September 8th and Friday, September 9th. 
Aug 04, 2016 05:05 pm ET
Sensus Healthcare Reports Second Quarter 2016 Results
BOCA RATON, Fla., Aug. 4, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today reported its financial results for the second quarter ended June 30, 2016.
Aug 02, 2016 12:33 pm ET
Sensus Healthcare to Announce Second Quarter 2016 Results on August 4, 2016
BOCA RATON, Fla., Aug. 2, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS; SRTSW), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today provided a reminder that it will report its second quarter 2016 financial results on Thursday, August 4, 2016 after the market close.
Aug 02, 2016 09:30 am ET
Sensus Healthcare, Inc. Names Anthony Petrelli to its Board of Directors
BOCA RATON, Fla., Aug. 2, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced the appointment of Anthony ("Tony") Petrelli to its Board of Directors. Mr. Petrelli is President, Chairman of the Board and Director of Investment Banking of Neidiger, Tucker, Bruner, Inc. ("NTB"), a SEC-registered broker-dealer firm.
Jul 25, 2016 09:30 am ET
Sensus Healthcare, Inc. Units Separate; Trading of Common Stock and Warrants Commences
BOCA RATON, Fla., July 25, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTSU), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today reported the separation of the 2,300,000 units issued in its underwritten initial public offering in accordance with their terms. Each unit will separate into one share of common stock, $0.01 par value per share, and a three-year warrant to purchase one share of common stock at an initial exercise price of $6.75 per share.
Jul 21, 2016 09:30 am ET
Sensus Healthcare, Inc. Announces Separation of Units Sold in IPO
BOCA RATON, Fla., July 21, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTSU), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced that the 2,300,000 units issued in its underwritten initial public offering will separate in accordance with their terms on July 25, 2016. Each unit consists of one share of common stock, $0.01 par value per share, and a three-year warrant to purchase one share of common stock at an initial exercise price of $6.75 per share.
Jun 08, 2016 11:26 am ET
Sensus Healthcare, Inc. Announces Completion of Initial Public Offering, including Underwriters' Exercise of Over-Allotment Option in Full
BOCA RATON, Fla., June 8, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTSU), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced the completion of its initial public offering of 2,300,000 units at a public offering price of $5.50 per unit, before underwriting discounts and commissions, which includes the exercise in full by the underwriters of their option to purchase up to 300,000 units at the initial public offering price. Each unit consists of one shar

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.